During the last session, BridgeBio Pharma Inc (NASDAQ:BBIO)’s traded shares were 0.46 million, with the beta value of the company hitting 1.04. At the end of the trading day, the stock’s price was $23.28, reflecting an intraday gain of 1.04% or $0.24. The 52-week high for the BBIO share is $44.32, that puts it down -90.38 from that peak though still a striking 7.13% gain since the share price plummeted to a 52-week low of $21.62. The company’s market capitalization is $4.40B, and the average intraday trading volume over the past 10 days was 2.07 million shares, and the average trade volume was 2.06 million shares over the past three months.
BridgeBio Pharma Inc (BBIO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.35. BBIO has a Sell rating from 0 analyst(s) out of 9 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 9 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.09.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BridgeBio Pharma Inc (NASDAQ:BBIO) trade information
BridgeBio Pharma Inc (BBIO) registered a 1.04% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.04% in intraday trading to $23.28, hitting a weekly high. The stock’s 5-day price performance is -3.44%, and it has moved by -4.79% in 30 days. Based on these gigs, the overall price performance for the year is -17.77%. The short interest in BridgeBio Pharma Inc (NASDAQ:BBIO) is 17.2 million shares and it means that shorts have 10.93 day(s) to cover.
The consensus price target of analysts on Wall Street is $46, which implies an increase of 49.39% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $19 and $58 respectively. As a result, BBIO is trading at a discount of -149.14% off the target high and 18.38% off the low.
BridgeBio Pharma Inc (BBIO) estimates and forecasts
Statistics show that BridgeBio Pharma Inc has outperformed its competitors in share price, compared to the industry in which it operates. BridgeBio Pharma Inc (BBIO) shares have gone down -16.14% during the last six months, with a year-to-date growth rate more than the industry average at 34.68% against 25.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -13.60% this quarter and then drop -536.00% in the quarter after that. In the rating firms’ projections, revenue will increase 2,999.49% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 43.39M as predicted by 13 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to 37.3M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 1.75M and 211.12M respectively. In this case, analysts expect current quarter sales to grow by 2,386.38% and then drop by -82.33% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -13.29%. While earnings are projected to return 35.38% in 2024, the next five years will return 26.80% per annum.
BBIO Dividends
BridgeBio Pharma Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
BridgeBio Pharma Inc (NASDAQ:BBIO)’s Major holders
BridgeBio Pharma Inc insiders own 5.41% of total outstanding shares while institutional holders control 94.45%, with the float percentage being 99.86%. KOHLBERG KRAVIS ROBERTS & CO. L.P. is the largest shareholder of the company, while 349.0 institutions own stock in it. As of 2024-06-30, the company held over 31.06 million shares (or 16.5582% of all shares), a total value of $786.77 million in shares.
The next largest institutional holding, with 25.12 million shares, is of VIKING GLOBAL INVESTORS LP’s that is approximately 13.3917% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $636.31 million.
Also, the Mutual Funds coming in first place with the largest holdings of BridgeBio Pharma Inc (BBIO) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Jun 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 4.52 shares. This amounts to just over 2.39 percent of the company’s overall shares, with a $105.07 million market value. The same data shows that the other fund manager holds slightly less at 3.64, or about 1.93% of the stock, which is worth about $84.62 million.
